53. Sjogren syndrome Clinical trials / Disease details
Clinical trials : 305 / Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05605665 (ClinicalTrials.gov) | November 5, 2022 | 29/10/2022 | Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome | Therapeutic Effect of Low Dose IL-2 Combined With Rapamycin in on sjögren's Syndrome | Sjögren's Syndrome | Drug: low-dose interleukin-2;Drug: rapamycin | Peking University People's Hospital | NULL | Recruiting | 18 Years | N/A | All | 30 | Phase 1/Phase 2 | China |